Synonyms: KW-0761 | mogamulizumab-kpkc | Poteligeo®
mogamulizumab is an approved drug (PMDA (Japan, 2012), EMA & FDA (2018))
Compound class:
Antibody
Comment: Mogamulizumab (KW-0761) is a CCR4-targeting mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) function. It is the only GPCR-targeting mAb on the market (in July 2017).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Bioactivity Comments |
Peptide sequence analysis of the heavy chain variable region of mogamulizumab matches sequence ID 9 from patent US7504104 [4], linking this antibody with clones Gal1LV1, Gal1LV2 or Gal1LV3. A graph of CCR4 binding by these antibody clones is provided in the patent, but no affinity value is specified. |
Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|